Biomarkers “indispensible” in cancer drug development, says Quintiles

By Gareth Macdonald

- Last updated on GMT

Biomarkers “indispensible” in cancer drug development, says Quintiles

Related tags Clinical trial

CRO Quintiles says biomarkers give insight into cancer drug candidates’ efficacy earlier in the development process, reducing trial costs and duration.

According to recent​ research, only 8 per cent of oncology new molecular entities (NMEs) reach the market and, worse still for drug sponsors keen to control clinical trial costs, six out of 10 candidates fail in Phase III testing.

Outsourcing-pharma discussed how biomarker analysis can improve cancer drug development with Quintiles VP of strategic business and oncology operations Christopher Ung.

Ung, who led the team that created HercepTest, explained that biomarkers are used in two ways: to identify patients likely to benefit from a drug; and in pharmacodynamic analysis to enable performance measurement early in a candidates’ development.

He went on to explain that recognition of such benefits has seen pharmaceutical industry demand for biomarkers surge over the last decade adding that, in a bid to meet this need, Quintiles has sought to match drug firms’ development processes.

And in the future Ung predicts that while established biomarker technologies will continue to support oncology development, newer technologies and models methods will continue to emerge to help drug industry efforts to combat cancer.

Related news

Show more

Related products

show more

How a Clinical MDR Helps with Data Quality

How a Clinical MDR Helps with Data Quality

Formedix | 16-Jan-2023 | Technical / White Paper

This article covers the many ways a clinical metadata repository helps with data quality in the clinical trial process, and how it ultimately helps to...

Optimizing Adherence in DCTs

Optimizing Adherence in DCTs

PPD - Decentralized Clinical Trials | 12-Jan-2023 | Technical / White Paper

Prioritizing greater patient-centricity and creating an opportunity to reach unprecedented patient groups, decentralized and hybrid clinical trials are...

PPD is Supporting Complex EU DCTs

PPD is Supporting Complex EU DCTs

PPD - Decentralized Clinical Trials | 05-Jan-2023 | Technical / White Paper

PPD supports European DCTs and clinical trial sponsors with a holistic and comprehensive approach

What should a clinical metadata repository do?

What should a clinical metadata repository do?

Formedix | 14-Dec-2022 | Technical / White Paper

Choosing a clinical metadata repository (MDR) software can be a tough task as the capabilities and features of your chosen MDR could make or break your...

Related suppliers

Follow us

Products

View more

Webinars